Page No- 1 PHARMACEUTICAL API PRODUCT LIST MAY 2012

Sr. No Molecule Name ONCOLOGY PRODUCTS 1 2 3 4 5 6 TEMOZOLOMIDE* CAPECITABINE IMATINIB PEMETREXED ERLOTINIB BORTEZOMIB STEROIDS 1 2 3 4 DUTASTERIDE NANDROLONE DECANOATE ROCURONIUM BROMIDE LOTEPREDNOL FERMENTATION PRODUCTS 1 HYALURONIC ACID OTHER PRODUCTS 1 ESZOPICLONE Sedative and Hypnotic Commercialized Ready Done Ready Osteoarthritis, Ophthalmic use Commercialized Ready Done BPH Product Hormonal, Anabolic Steroid Muscle Relaxant Corticosteroid for Ophthalmic use Commercialized Commercialized Commercialized Commercialized Ready Ready Ready Ready Done Done Done Done Ready Ready Ready Ready Antineoplastic Antineoplastic Antineoplastic Antineoplastic Antineoplastic Antineoplastic Commercialized Commercialized Commercialized Commercialized Commercialized Commercialized Ready Ready Ready Ready Ready Ready Done Done Done Done Done Done Ready Ready Ready Ready Ready August 2012 Therapeutic Category Development Priority Lab Samples Validation Batches DMF

* Product only available for offer in markets other than North America, Australia, Japan.

PHARMACEUTICAL API DEVELOPMENT LIST

Sr. No Molecule Name ONCOLOGY PRODUCTS 1 2 3 4 5 LENALIDOMIDE DECITABINE SUNITINIB SORAFENIB AZACITIDINE STEROIDS AND HORMONES 1 FULVESTRANT PEPTIDES 1 2 1 LEUPROLIDE GOSERELIN OTHER PRODUCTS PARICALCITOL Vitamin D Analogue August 2012 Prostate cancer or breast cancer, estrogen-dependent conditions Hormone Sensitive Cancers Ready August 2012 Estrogen Receptor Antagonist August 2012 Antineoplastic Antineoplastic Antineoplastic Antineoplastic Antineoplastic Ready Ready August 2012 Ready Ready Therapeutic Category Lab Samples

The above products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Reliance Life Sciences Private Limited offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction.

P. T. O

Page No- 2 PHARMACEUTICAL FINISHED DOSAGE FORMS DEVELOPMENT LIST MAY 2012
Sr. No

Molecule Name ONCOLOGY PRODUCTS

Strength

Dosage Form

Therapeutic Category

Dossier

CAPECITABINE

150 mg and 500 mg 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg

Tablet

Antineoplastic

November 2012 November 2012 December 2012 January 2013

TEMOZOLOMIDE

Capsule

Antineoplastic

3 4

BORTEZOMIB PEMETREXED

1 mg and 3.5 mg 100 mg and 500 mg

Vial Vial

Antineoplastic Antineoplastic

HORMONAL API PRODUCT LIST

Sr. No Molecule Name HORMONES 1 2 3 4 5 6 7 8 ESTRADIOL ESTRIOL TESTOSTERONE ESTRADIOL VALERATE TESTOSTERONE CYPIONATE DROSPIRENONE DESOGESTREL DYDROGESTERONE Hormonal Hormonal Hormonal, Anabolic Steroid Hormonal Hormonal, Anabolic Steroid Pre Menstrual pain, Birth control Oral Contraceptive Hormonal Developed Developed Developed Developed Developed Developed Developed Under Development Ready Ready Ready Ready Ready Ready Ready TBD TBD TBD TBD TBD TBD TBD TBD TBD Therapeutic Category Development Priority Lab Samples Validation Batches

The above products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Reliance Life Sciences Private Limited offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction.